The rapid evolution of Generative AI (GenAI) technologies has the potential to accelerate drug discovery, improve patient engagement, streamline operations, and drive significant advancements in personalized medicine.
Explore how USDM leverages remote audits with virtual tools like AR, VR, and cloud systems to streamline vendor qualification and regulatory compliance.
Learn about 21 CFR Part 11, the FDA regulation ensuring the security, traceability, and compliance of electronic records and eSignatures in life sciences.
